Seasoned CEO and Veteran Marketer Brings Decades of Healthcare Leadership Experience and Proven Results

NEW YORK--(BUSINESS WIRE)--BGB Group (BGB or the "Company"), an award-winning healthcare commercialization and communications company headquartered in New York City with offices in Washington DC, Boston, and London, today announced the appointment of David Coman as Chief Executive Officer and a member of the Company's Board of Directors, effective immediately. Greg Passaretti and Brendon Phalen, Founding Partners, will continue to support BGB and key client relationships, and continue to serve on the Company's Board.

"We founded BGB in 2005 with the goal to create an agency that leads our clients into the future. As our industry continues to become more sophisticated, we knew we needed a leader who is native to the new data and tech-driven commercialization model, and who has built successful businesses in dynamically evolving markets," said Passaretti. "David's background and expertise align with the current direction of the market and his leadership style and genuine enthusiasm align with BGB's culture and client-first mindset," added Phalen. "Greg and I could not be more excited to welcome David and partner with him to support BGB's continued growth."

Coman brings to BGB an extraordinary set of experiences, with an emphasis on leveraging data and technology to drive analytics. He also has deep experience building pharmaceutical services businesses through both organic growth, as well as strategic acquisitions and partnerships. Most recently, David served as the CEO of Science 37, a pioneer in decentralized clinical trials. Earlier in his career, Coman served as Chief Strategy Officer at ERT (now Clario), Chief Marketing Officer at Quintiles (now IQVIA), and Chief Marketing Officer at Dendrite (now part of IQVIA). He started his career at Young & Rubicam, a market-leading global advertising agency, working on businesses that ranged from AT&T to Xerox.

"Led by Greg and Brendon, BGB has – for nearly two decades – seamlessly merged scientific acumen and creative innovation to develop high-impact campaigns for healthcare professionals, patients, caregivers, advocacy groups, and policy makers," said Coman. "The company is now at an exciting inflection point, where we have an opportunity to continue to bolster BGB's core capabilities, while building new ones to meet the market where it is going. The future of BGB is incredibly bright and it's an honor to lead this team as we evolve and enhance BGB's capabilities, expand the portfolio of our partner agencies, and deliver the personalized solutions that our consumers have come to expect."

In 2021, BGB partnered with TPG, a global alternative asset management firm, to accelerate growth through continued organic expansion, as well as strategic partnerships and acquisitions. During this time, the Company has grown its leading medical communications and HCP advertising businesses, while adding meaningful and complementary offerings in data/analytics, strategic consulting, and market access.

"A seasoned pharma services executive with more than 20 years in pharmaceutical commercialization and clinical leadership positions, David is well-suited to lead the next phase of growth at BGB and we are pleased to welcome him to the team," said Matthew Hobart, Co-Managing Partner of TPG Growth and Chairman of BGB's Board. "Greg and Brendon's vision, creativity, and leadership have been critical to BGB's success, and together with David, Greg, Brendon, and the boarder team, we look forward to continuing TPG's partnership with BGB to build on the Company's momentum."

About BGB Group:

At BGB group, we challenge ourselves to go beyond the measures of success that defined the industry to date. We seamlessly integrate scientific smarts, strategic prowess, creativity, innovation, and technology to push boundaries and build sophisticated and meaningful solutions to our clients' challenges. Our specialized teams in healthcare promotion, medical education, strategic consulting, and payer marketing partner and collaborate to discover new opportunities, move markets, and accelerate impact for our clients and their businesses.

About TPG:

TPG is a leading global alternative asset management firm, founded in San Francisco in 1992, with $239 billion of assets under management and investment and operational teams around the world. TPG invests across a broadly diversified set of strategies, including private equity, impact, credit, real estate, and market solutions, and our unique strategy is driven by collaboration, innovation, and inclusion. Our teams combine deep product and sector experience with broad capabilities and expertise to develop differentiated insights and add value for our fund investors, portfolio companies, management teams, and communities.

Media:
BGB Group
Amanda Eckel
aeckel@bgbgroup.com

TPG
Julia Sottosanti
media@tpg.com